| 2026-06-16 16:43 |
8-K |
["1.01", "2.01"] |
tender offer |
1.00
|
Completed tender offer and merger with Zydus Worldwide DMCC at $23.50/share; 66.32% acceptance rate. |
SEC · detail |
| 2026-06-16 07:31 |
SC 14D9 |
|
tender offer |
0.98
|
SC 14D9/A amendment confirming tender offer completion: 66.32% of shares tendered at $23.50/share, merger closing June 16, 2026. |
SEC · detail |
| 2026-05-18 17:18 |
SC 14D9 |
|
tender offer |
0.98
|
SC 14D9 response to tender offer by Zydus Worldwide DMCC at $23.50/share under merger agreement dated May 13, 2026. |
SEC · detail |
| 2026-05-18 16:08 |
SC TO-T |
|
tender offer |
0.99
|
Zydus Lifesciences filing SC TO-T for cash tender offer to acquire Assertio Holdings at $23.50/share. |
SEC · detail |
| 2026-05-18 09:23 |
8-K |
["8.01"] |
tender offer |
0.98
|
Assertio entered into merger agreement with Zydus Worldwide DMCC; $23.50/share cash tender offer commences May 18, 2026. |
SEC · detail |
| 2026-05-13 09:03 |
8-K |
["1.01"] |
merger agreement |
0.99
|
Assertio entered definitive merger agreement with Zydus Worldwide for $23.50/share cash tender offer. |
SEC · detail |
| 2026-05-08 08:13 |
8-K |
["7.01", "9.01"] |
merger agreement |
0.98
|
Assertio merger agreement with Garda Therapeutics; tender offer deadline extended to May 14, 2026. |
SEC · detail |
| 2026-05-07 17:00 |
8-K |
["5.02", "5.07", "9.01"] |
other |
0.05
|
Routine annual meeting with director elections, equity plan increase, and auditor ratification—no M&A signals. |
SEC · detail |
| 2026-05-05 09:07 |
8-K |
["7.01", "9.01"] |
merger agreement |
0.98
|
Assertio in merger agreement with Garda Therapeutics; tender offer deadline extended to May 8, 2026. |
SEC · detail |
| 2026-05-04 08:21 |
8-K |
["1.01"] |
merger agreement |
0.98
|
Assertio entered definitive amended merger agreement with Garda Therapeutics for $21.80/share cash offer. |
SEC · detail |
| 2026-04-29 17:07 |
8-K |
["7.01", "9.01"] |
merger agreement |
0.95
|
Assertio Holdings in definitive merger agreement with Garda Therapeutics; tender offer deadline extended to May 4, 2026. |
SEC · detail |